Free Trial
NASDAQ:UNCY

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

Unicycive Therapeutics logo
$0.51 +0.02 (+4.09%)
(As of 11/20/2024 ET)

About Unicycive Therapeutics Stock (NASDAQ:UNCY)

Key Stats

Today's Range
$0.47
$0.55
50-Day Range
$0.36
$0.59
52-Week Range
$0.20
$1.82
Volume
1.69 million shs
Average Volume
1.23 million shs
Market Capitalization
$52.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.13
Consensus Rating
Buy

Company Overview

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

UNCY MarketRank™: 

Unicycive Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 344th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Unicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Unicycive Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Unicycive Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.23) to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Unicycive Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Unicycive Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    1.24% of the float of Unicycive Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Unicycive Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Unicycive Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Unicycive Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.24% of the float of Unicycive Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Unicycive Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Unicycive Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Unicycive Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    15 people have searched for UNCY on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.10% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Unicycive Therapeutics' insider trading history.
Receive UNCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UNCY Stock News Headlines

Brookline Capital Management Forecasts UNCY FY2024 Earnings
HC Wainwright Brokers Increase Earnings Estimates for UNCY
Tesla Execs are Freaking Out
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
Unicycive Therapeutics (UNCY) Gets a Buy from Noble Financial
Unicycive Therapeutics expects cash to fund operations into 2026
Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
See More Headlines

UNCY Stock Analysis - Frequently Asked Questions

Unicycive Therapeutics' stock was trading at $0.8677 on January 1st, 2024. Since then, UNCY shares have decreased by 41.3% and is now trading at $0.5094.
View the best growth stocks for 2024 here
.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.26.

Unicycive Therapeutics (UNCY) raised $25 million in an IPO on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

Top institutional investors of Unicycive Therapeutics include Great Point Partners LLC (9.07%), Walleye Capital LLC (5.30%), Acuta Capital Partners LLC (2.10%) and Bleakley Financial Group LLC (0.08%).
View institutional ownership trends
.

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET).

Company Calendar

Last Earnings
11/11/2021
Today
11/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UNCY
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.13
High Stock Price Target
$9.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+906.1%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-30,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
($0.11) per share

Miscellaneous

Free Float
78,781,000
Market Cap
$52.87 million
Optionable
Not Optionable
Beta
2.29
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:UNCY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners